4SC AG decides on an increase in share capital

(lifePR) (Planegg-Martinsried, Germany, ) Today, the Management Board of the Martinsried-based drug discovery and development company 4SC AG (Frankfurt, Prime Standard: VSC), with the approval of the Supervisory Board, decided to increase the share capital from 19,001,826.00 Euros to up to 28,502,739.00 Euros, by issuing up to 9,500,913 zero par value common bearer shares from the authorised capital. The new shares are to be offered to the shareholders at a subscription price of 3.10 Euros per new share.

The proceeds of the capital increase are to be used for financing the acquisition of Nycomed's oncology projects in the amount of 14 million Euros (compare Ad Hoc announcement of 4SC AG dated 4 June 2008) and to further develop the existing as well as the new project pipeline of 4SC AG.

The subscription rights of the shareholders are complied with. The shareholders can subscribe to the new shares with dividend rights from 1 January 2008 in a 2:1 ratio starting from 25 June 2008 until 10 July 2008. In the following unsubscribed shares are to be offered to institutional investors. A public offer for the purchase of the new shares is not planned. The admission of the new shares for trading at the Frankfurt Stock Exchange is not expected before November/December 2008.

Further details of the capital increase will be provided in the subscription offer expected to be published in the electronic Federal Gazette on 25 June 2008.

Kontakt

4SC AG
Fraunhoferstr. 22
D-82152 Planegg-Martinsried
Bettina von Klitzing
4SC AG
Manager Public Relations & Investor Relations
Social Media